News

Pfizer’s Braftovi Doubles Survival in Advanced Colorectal Cancer
A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...
The Joplin Globe7d
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer ...